PGC-1α, Sirtuins and PARPs in Huntington’s Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All.

PGC-1α, Sirtuins and PARPs in Huntington’s Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All.

Publication date: May 07, 2019

In this review, we summarize the available published information on the neuroprotective effects of increasing nicotinamide adenine dinucleotide (NAD) levels in Huntington’s disease models. We discuss the rationale of potential therapeutic benefit of administering nicotinamide riboside (NR), a safe and effective NAD precursor. We discuss the agonistic effect on the Sirtuin1-PGC-1α-PPAR pathway as well as Sirtuin 3, which converge in improving mitochondrial function, decreasing ROS production and ameliorating bioenergetics deficits. Also, we discuss the potential synergistic effect of increasing NAD+ combined with PARPs inhibitors, as a clinical therapeutic option not only in HD, but other neurodegenerative conditions.

Concepts Keywords
Adenine Alpha
Agonistic NAD(P)+ transhydrogenase
Bioenergetics NAD(P)H dehydrogenase
Huntington Vitamins
Mitochondrial Nicotinamide riboside
NAD Nicotinamide adenine dinucleotide
NAD+ Sirtuin
Neurodegenerative Enzymes
Neuroprotective Catalysts
Nicotinamide Cellular respiration
PPAR
ROS
Sirtuin
Synergistic

Semantics

Type Source Name
gene UNIPROT ROS1
drug DRUGBANK Rosoxacin
gene UNIPROT PPARA
drug DRUGBANK Nicotinamide
gene UNIPROT PGC
drug DRUGBANK Nadide

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *